Microdosing magic mushrooms has entered the mainstream in a big way: investors have staked billions on possible medical treatments, scientific research has skyrocketed and public sentiment signals growing acceptance. Yet the main sources of drug use data have big gaps when it comes to psychedelics, making it difficult to get an accurate picture of how and why people are using them. Two new reports out this week offer much-needed insight into the psychedelic zeitgeist, showing that microdosing is on the rise.

Microdosing is defined as taking very low, sub-hallucinogenic doses of a psychedelic, such as lysergic acid diethylamide or psilocybin mushrooms. Those who practice it claim the drugs boost their moods and creativity and make the world around them seem richer, more colorful and higher definition. Typically, microdoses are consumed several times per week and at a level lower than what would cause a hallucinogenic high.

Exploring the Effects of Microdosing Magic Mushrooms

The latest report found that psilocybin is the most popular psychedelic among microdoses. The runner-up was MDMA, also known as ecstasy. Both of these drugs are legal in some states, but many people report buying their psilocybin from underground dealers. The report also found that a person’s state of residence seems to affect their choice of psychedelic, with Oregon and Colorado topping the list for mushroom users.

It’s important for those thinking about microdosing to assess their physical and mental wellbeing before starting a cycle. A checkup with a primary care physician can reveal any underlying conditions that could be exacerbated by psychedelics. A psychological health assessment, such as a daily journal or psychometric measures of depression, anxiety and flow can also help.